Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation

Leukemia Research
10 Jul, 2020 ,

Alec Britt conducted a study to assess if poor outcomes extend to patients with all types of ch17 abnormalities and the impact of concomitant TP53 gene mutations assessed by next-generation sequencing on prognosis. The researchers concluded that AML/MDS patients with ch17 abnormalities have poor outcomes with or without hematopoietic cell transplant . The results show that patients with ch17 abnormalities and TP53 mutations have a significantly poorer survival compared to patients who have ch17 abnormalities but no TP53 mutations.